Ginkgo Bioworks Holdings Market Cap ($625.28 Million)
Market Cap & Net Worth: Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks Holdings market cap. Ginkgo Bioworks Holdings (NYSE:DNA) has a market capitalization of $625.28 Million ($625.28 Million) as of November 7, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #10777 globally and #2848 in its home market, demonstrating a -11.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ginkgo Bioworks Holdings's stock price $11.29 by its total outstanding shares 55383808 (55.38 Million). Also see cash flow conversion of Ginkgo Bioworks Holdings for how efficiently the company converts equity into cash flow.
Ginkgo Bioworks Holdings Market Cap History (2021–2026)
Ginkgo Bioworks Holdings market cap history from 2021 to 2026. Data shows change from $18.41 Billion to $625.28 Million (-47.51% CAGR). Check DNA share price today for real-time trading data and today's change.
Ginkgo Bioworks Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ginkgo Bioworks Holdings's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Ginkgo Bioworks Holdings (DNA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.70x
Ginkgo Bioworks Holdings's market cap is 2.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $18.41 Billion | $313.84 Million | -$1.83 Billion | 58.66x | N/A |
| 2022 | $3.74 Billion | $477.71 Million | -$2.10 Billion | 7.84x | N/A |
| 2023 | $3.74 Billion | $251.46 Million | -$892.87 Million | 14.89x | N/A |
| 2024 | $543.87 Million | $227.04 Million | -$547.03 Million | 2.40x | N/A |
| 2025 | $460.24 Million | $170.16 Million | -$312.76 Million | 2.70x | N/A |
Competitor Companies of DNA by Market Capitalization
Companies near Ginkgo Bioworks Holdings in the global market cap rankings as of November 7, 2026. Also see Ginkgo Bioworks Holdings asset portfolio for a full breakdown of the balance sheet.
Key companies related to Ginkgo Bioworks Holdings by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Ginkgo Bioworks Holdings (2021–2026)
Market capitalization of Ginkgo Bioworks Holdings from 2021 to today. Between 2021 and today, Ginkgo Bioworks Holdings's market cap moved from $18.41 Billion to $ 625.28 Million, with a yearly change of -47.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $625.28 Million | +35.86% |
| 2025 | $460.24 Million | -15.38% |
| 2024 | $543.87 Million | -85.47% |
| 2023 | $3.74 Billion | 0.00% |
| 2022 | $3.74 Billion | -79.66% |
| 2021 | $18.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Ginkgo Bioworks Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $625.28 Million USD |
| MoneyControl | $625.28 Million USD |
| MarketWatch | $625.28 Million USD |
| marketcap.company | $625.28 Million USD |
| Reuters | $625.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more